Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

GILD.NASDAQ

Gilead Sciences

Healthcare | Drug Manufacturers - General

Biopharmaceutical company discovering, developing, and commercializing innovative medicines in areas of unmet medical need.

Flagship Insight

Why the Market Miscalculates the Longevity of This Virology Giant's Moat

There is high consensus that the market systematically misprices this asset's long-acting virology transition and extended patent protection. While near-term acquisitions distort reported earnings, the primary driver remains robust free cash flow generation, while regulatory pricing pressure acts as the main friction.

Forecast TimelineUpdated On Jul 02 2026

Gilead Sciences (GILD) Stock Forecast and AI Rating

Recommendation

Small Buy

Open a small position; wait before adding more.

2027

1-Year

BUY

$148

+12.8%

+15.3% IF INCL. DIVS

2029

3-Year

N/A

$171

+32%

2031

5-Year

BUY

$194

+48%

+68% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The asset represents a highly resilient defensive compounder positioned to outperform in a stagflationary macro regime characterized by elevated interest rates and sticky inflation. The core investment thesis centers on the structural transition of its dominant virology franchise from daily oral regimens to long-acting injectables, which effectively extends the patent runway and neutralizes generic erosion. While recent high-premium acquisitions and in-process research and development charges temporarily distort reported GAAP earnings, the underlying free cash flow engine remains pristine, supported by an asset-light operating model and elite gross margins.

Key insights

Legally secured patent settlements extend the core virology franchise exclusivity, providing a highly predictable cash flow floor.
The commercial ramp of long-acting injectables expands the preventative total addressable market by solving patient compliance bottlenecks.
High capital efficiency and minimal physical capital expenditure requirements insulate the asset from rising interest rates and inflationary pressures.
Strategic oncology expansion diversifies the revenue base, though historical high-premium acquisitions introduce capital allocation risks.
Regulatory pricing frameworks and federal drug price negotiations present persistent headwinds to net realized margins.
Robust free cash flow conversion supports aggressive share repurchases and consistent dividend growth, establishing a strong valuation floor.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Gilead Sciences quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Gilead Sciences.
Quarter	Forecast date	Bear Case (USD)	Base Case (USD)	Bull Case (USD)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 02, 2026	$133.90	$135.54	$137.83	$736.09
Quarter 2+6M	Jan 02, 2027	$132.56	$139.39	$143.35	$724.14
Quarter 3+9M	Apr 02, 2027	$133.83	$142.66	$149.08	$713.57
Quarter 4+1Y	Jul 02, 2027	$139.18	$146.58	$155.02	$723.38
Quarter 5+15M	Oct 02, 2027	$136.48	$148.05	$158.12	$716.61
Quarter 6+18M	Jan 02, 2028	$137.71	$150.90	$162.86	$738.34
Quarter 7+21M	Apr 02, 2028	$144.59	$154.63	$166.16	$746.91
Quarter 8+2Y	Jul 02, 2028	$147.48	$156.76	$169.49	$771.93
Quarter 9+27M	Oct 02, 2028	$148.96	$160.00	$172.81	$782.73
Quarter 10+30M	Jan 02, 2029	$143.00	$161.81	$172.74	$807.31
Quarter 11+33M	Apr 02, 2029	$147.29	$164.03	$177.92	$822.72
Quarter 12+3Y	Jul 02, 2029	$153.18	$168.10	$181.48	$846.10
Quarter 13+39M	Oct 02, 2029	$151.88	$171.33	$185.11	$852.53
Quarter 14+42M	Jan 02, 2030	$153.12	$174.47	$190.66	$882.91
Quarter 15+45M	Apr 02, 2030	$157.71	$177.25	$191.97	$900.46
Quarter 16+4Y	Jul 02, 2030	$164.02	$178.80	$192.53	$922.67
Quarter 17+51M	Oct 02, 2030	$162.38	$182.30	$196.38	$935.91
Quarter 18+54M	Jan 02, 2031	$167.25	$186.07	$202.27	$952.30
Quarter 19+57M	Apr 02, 2031	$170.60	$189.45	$207.57	$976.28
Quarter 20+5Y	Jul 02, 2031	$172.61	$193.88	$211.72	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in the market's systematic mispricing of the virology franchise's terminal duration and the strategic value of its cash flow. While the crowd fixates on a near-term patent cliff, legal settlements have quietly extended key patent protections out to 2036. Furthermore, the transition to long-acting injectables represents a compliance paradigm shift that structurally expands the preventative market rather than merely cannibalizing existing sales. In a restrictive monetary regime, the company's massive free cash flow acts as a predatory weapon, allowing it to acquire distressed biotech innovation at cycle-trough valuations. The market prices the asset as a decaying annuity, failing to recognize its evolution into an adaptive, highly capitalized compounder.

Advisor Disagreement

The primary disagreement across the reports centers on the valuation and return on investment of the oncology pipeline. Some perspectives view historical acquisitions as value-destroying write-offs that will permanently drag on returns, while others argue that these assets are successfully establishing a critical secondary growth engine. Additionally, there is minor divergence regarding the timing of the market's re-rating, with assumptions split between near-term regulatory catalysts and a slower, macro-driven defensive rotation.

Financial Reviews by iPulse AI

Earnings and financials

The consensus shows that the company's financial engine is incredibly strong and recovering rapidly. After a temporary drop in reported profits in 2024 due to one-time acquisition costs, earnings bounced back sharply in 2025, with annual free cash flow consistently exceeding ten billion dollars. While overall revenue growth is slow and steady, the company's ability to turn sales into actual cash is outstanding. There is broad agreement that this massive cash flow provides a powerful safety net during economic downturns. However, opinions differ on the future growth path: some expect steady, flat performance as older products face competition, while others anticipate a growth breakout as new treatments hit the market. Overall, the financial health is highly supportive, offering retail investors a reliable, low-risk cash generator.

Profitability and margins

The company boasts elite profitability, highlighted by gross margins near eighty percent, which reflects its immense pricing power and the low cost of producing its core medicines. Operating margins have normalized around a robust forty percent after recovering from past acquisition write-offs. Analysts agree that these high margins provide a strong buffer against inflation and rising business costs. However, there is a clear clash of opinions regarding future margin trends. Some warn that government price negotiations and political pressure to lower drug costs will inevitably squeeze profit margins over time. Others argue that the high-margin nature of new long-acting treatments will easily offset these regulatory pressures. Overall, the margin profile remains a key structural advantage, protecting real earnings power in a challenging economic environment.

Balance sheet and leverage

The company's balance sheet is a verified financial fortress, recently upgraded by major rating agencies. With manageable debt levels and an exceptional ability to cover its interest payments, the business is highly insulated from rising interest rates and credit market stress. Analysts universally agree that this financial strength provides excellent downside protection, ensuring the company can easily pay its attractive dividend and continue buying back its own shares. Furthermore, this strong position gives the company the financial firepower to make opportunistic purchases of smaller, struggling biotech firms during market downturns. There is virtually no disagreement on the safety of the balance sheet, making it a highly reliable anchor for conservative investors seeking capital preservation in a volatile market.

Capex and investment intensity

The company operates an extremely capital-light business, spending less than two percent of its revenue on physical buildings and equipment. Instead, its true investment focus is on research and development, where it spends nearly six billion dollars annually to develop new drugs and protect its market position. Analysts agree that this low physical spending is a major advantage because it leaves more cash available for dividends and stock buybacks. However, there is some disagreement regarding the company's heavy spending on acquisitions. Some view these multi-billion-dollar purchases as necessary to replace older drugs before their patents expire, while others worry that the company is overpaying for unproven technologies. Monitoring how efficiently these investments turn into profitable new treatments remains key for long-term investors.